IPO - Aspira Women's Health Inc.

Form Type: S-1/A

Filing Date: 2025-05-06

Corporate Action: Ipo

Type: Update

Accession Number: 000164117225008770

Filing Summary: Aspira Women's Health Inc. has filed a registration statement with the SEC for the resale of a total of 354,988 shares of common stock and an additional 42,328,042 shares to be issued to Triton Funds LP under the Purchase Agreement. The shares were issued for a commitment of $25,000 and part of a broader commitment to purchase up to $2,000,000 worth of shares until September 30, 2025. The company was recently delisted from Nasdaq and is now trading on the OTC Markets under the symbol 'AWHL'. Aspira is classified as a smaller reporting company under federal securities laws and aims to proceed with the sale as soon as the registration statement becomes effective. Investors should be aware that investing in these securities involves high risks, and the prospectus includes a discussion of risk factors associated with this investment.

Form Type: S-1

Filing Date: 2025-04-16

Corporate Action: Ipo

Type: New

Accession Number: 000164117225004935

Filing Summary: Aspira Women's Health Inc. filed Form S-1 with the SEC for a registration statement under the Securities Act of 1933 on April 15, 2025. The company is offering up to 354,988 shares of common stock and aims to raise up to $2,000,000 through a common stock purchase agreement with Triton Funds LP. The agreement allows the company to require Triton to purchase shares between the effective date of the registration statement and September 30, 2025. The selling stockholder has purchased shares for a commitment amount of $25,000. The company operates in the healthcare sector focusing on the development and commercialization of non-invasive, AI-powered diagnostic tests for gynecologic diseases, particularly ovarian cancer and endometriosis. Aspira intends to use the net proceeds from the sale of common stock for commercial activities and general corporate purposes. The risks of investing in the securities are highlighted, emphasizing the speculative nature of the investment and potential dilution for existing shareholders. Additionally, Aspira is classified as a 'smaller reporting company' under federal securities laws, allowing it certain exemptions from full disclosure requirements.

Form Type: S-1/A

Filing Date: 2025-02-11

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225005769

Filing Summary: This document, filed with the SEC, serves as the second amendment to the registration statement for Aspira Women's Health Inc. under the Securities Act. The company is proposing to offer up to 50,000,000 Units, with each Unit comprising one share of common stock and one warrant to purchase one share of common stock. Additionally, the registration includes 50,000,000 Pre-Funded Units, each consisting of one pre-funded warrant to purchase one share of common stock along with one warrant. The company is in the process of preparing for the sale of these securities and continues to fulfill the requirements for the registration to become effective. The anticipated commencement of sales is scheduled to begin as soon as practicable after the registration statement is approved by the SEC. The document elaborates on various applicable regulations, definitions, and the company’s classification as a smaller reporting and emerging growth company. Legal representatives are identified for further contacts regarding the filing, ensuring proper procedures are adhered to for compliance with the SEC regulations. There are indications of ongoing negotiations and details about previous offering amendments as well as relevant financial structures.

Form Type: S-1/A

Filing Date: 2025-01-31

Corporate Action: Ipo

Type: Update

Accession Number: 000149315225004349

Filing Summary: Aspira Women's Health Inc. is amending their registration statement for an initial public offering (IPO) under the Securities Act of 1933. The company is offering up to 50,000,000 units consisting of one share of common stock and one warrant to purchase one share of common stock, with a proposed public offering price of $0.40 per unit, based on the last sale price reported on The Nasdaq Capital Market on January 27, 2025. The amendment indicates that the offering will commence as soon as the registration statement becomes effective. The registration statement also clarifies that the nature of the offering may be subject to changes and that it does not constitute an offer to sell or solicit an offer to buy these securities until it is effective. Aspira Women's Health is identified as a smaller reporting company and has noted that they are not using the extended transition period for complying with new financial accounting standards.

Form Type: S-1

Filing Date: 2025-01-08

Corporate Action: Ipo

Type: New

Accession Number: 000149315225001451

Filing Summary: Aspira Women’s Health Inc. is filing a Registration Statement under the Securities Act of 1933 for an initial public offering (IPO) of up to 16,000,000 shares of common stock and up to 16,000,000 pre-funded warrants. The offering price is set at an assumed public offering price of $0.75 per share based on the last reported sale price on January 7, 2025. The pre-funded warrants will allow purchasers to buy shares at an exercise price of $0.001 each. The company aims to expand its commercial focus to diagnose various gynecologic diseases, including ovarian cancer and endometriosis through new AI-enabled diagnostic tests. Aspira plans to utilize its diagnostic platforms to enhance market penetration while continuing efforts to raise public awareness and establish insurance coverage for its tests. The document also outlines the company’s past growth and future projections based on its strategic initiatives in product development, commercial partnerships, and patient access advocating for legislative support.